PRA-023 is under clinical development by Prometheus Biosciences and currently in Phase II for Crohn’s Disease (Regional Enteritis). According to GlobalData, Phase II drugs for Crohn’s Disease (Regional Enteritis) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PRA-023’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRA-023 is under development for the treatment of inflammatory bowel diseases like ulcerative colitis, crohn's disease and systemic sclerosis-associated interstitial lung disease (SSc-ILD). The drug comprises of humanized IgG1 monoclonal antibody and is administered through intravenous and subcutaneous route. It acts by targeting tumor necrosis factor (TNF)-like cytokine 1A (TL1A).
Prometheus Biosciences overview
Prometheus Biosciences is the biotech company that discover, develops and commercializes novel therapeutic and companion diagnostic product candidates for inflammatory bowel disease (IBD). The company’s pipeline products include PRA023, an anti-TL1A mAb for the treatment of ulcerative colitis and crohn’s disease; and PR600, PR300, PR1100, PR1800 and PR2100 against inflammatory bowel disease (IBD). It utilizes Prometheus360, a medicine platform that combines machine learning-based analytical process to develop its products. Prometheus Biosciences is also investigating therapeutics for gastrointestinal (GI) diseases targeting other autoimmune diseases. Prometheus Biosciences is headquartered in San Diego, California, the US.
For a complete picture of PRA-023’s drug-specific PTSR and LoA scores, buy the report here.